Recent developments include the company’s full year 2025 financial results announcement, receipt of a U.S. patent for AGMB-447, and completion of its initial public offering in early 2026.

• Agomab reported full year 2025 financial results and confirmed its 2026 outlook in April 2026 [N1].
• The company received a U.S. patent for AGMB-447, its inhaled lung-restricted ALK5 inhibitor for idiopathic pulmonary fibrosis, in March 2026 [N2].
• Agomab announced the closing of its initial public offering in February 2026, raising gross proceeds of $207.7 million [N3].
• The pricing of the initial public offering was announced in early February 2026 [N4].

Agomab’s lead candidate ontunisertib has demonstrated safety and tolerability in a Phase 2a trial with positive exploratory clinical signals in Fibrostenosing Crohn’s Disease, a condition with no approved pharmacologic treatments. The gastrointestinal-restricted design may offer a differentiated safety profile. AGMB-447’s inhaled delivery and lung-restricted exposure could provide advantages in idiopathic pulmonary fibrosis treatment, supported by positive preclinical data and regulatory orphan drug designation. The company’s recent IPO provides capital to advance clinical programs, including planned Phase 2b and Phase 2 proof-of-concept trials. The focused pipeline targeting well-validated fibrosis pathways with organ-restricted approaches may address significant unmet medical needs and large patient populations.

Agomab is a clinical-stage company with no approved products and no reported revenues, relying on successful clinical development and regulatory approvals to achieve commercial viability. The fibrosis therapeutic area is competitive with multiple large and established companies developing ALK5 inhibitors and other anti-fibrotic agents. Clinical trials may not confirm efficacy or safety signals observed to date. Manufacturing relies on third-party providers, which may pose supply risks. Pricing, reimbursement, and regulatory challenges could impact future commercialization. The company’s financial disclosures do not provide detailed financial metrics, limiting visibility into its financial health and runway.

Agomab’s moat is based on its focused pipeline of organ-restricted ALK5 inhibitors designed to overcome systemic toxicity challenges that have limited previous TGFβ pathway inhibitors. The company’s lead candidates have demonstrated localized exposure profiles and safety in clinical and preclinical studies, supported by regulatory designations such as Fast Track and Orphan Drug status. The proprietary approach to targeting fibrosis with organ-restricted small molecules and antibodies, combined with a strong intellectual property portfolio including patents for AGMB-447, provides differentiation. Additionally, the experienced management team with deep scientific and clinical expertise and successful capital markets experience supports execution. However, the company faces competition from larger pharmaceutical companies and other biotechs developing fibrosis therapies, and its clinical-stage status means commercial success depends on future clinical and regulatory outcomes.

• Clinical Development Risk: The company’s product candidates are in early clinical stages and may fail to demonstrate safety or efficacy in ongoing or future trials.
• Regulatory Risk: Obtaining marketing approval is uncertain and subject to regulatory scrutiny, which may delay or prevent product commercialization.
• Competition Risk: Agomab faces competition from larger pharmaceutical companies and other biotechs developing fibrosis therapies, which may impact market share and pricing.
• Manufacturing and Supply Risk: Dependence on third-party contract manufacturers may lead to supply disruptions or quality control issues.
• Financial Risk: Limited financial disclosures and clinical-stage status imply reliance on capital markets and funding availability to sustain operations and development.

• Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need [S1].
• The company is headquartered in Antwerp, Belgium, with chemistry laboratory facilities in Touro, Spain, and an office in Cambridge, Massachusetts, USA [S1].
• Agomab's ADSs have been listed on the Nasdaq Global Select Market under ticker 'AGMB' since February 6, 2026 [S1].
• The company raised gross proceeds of $207.7 million in its initial public offering in February 2026 [S1][N3][N4].
• Agomab's executive team includes CEO Tim Knotnerus, CMO Philippe Wiesel, CFO Pierre Kemula, Chief Development Officer Andrea Sáez, Chief Business Officer Paul van der Horst, and General Counsel Ellen Lefever, all with significant industry and clinical development experience [S1].
• The company acquired 100% of Agomab Spain in December 2021, which included the discovery of its lead product candidates ontunisertib (AGMB-129) and AGMB-447 [S1].
• Agomab's lead product candidate, ontunisertib (AGMB-129), is a selective and potent oral gastrointestinal-restricted small molecule inhibitor of ALK5 (TGFβR1) in development for Fibrostenosing Crohn's Disease (FSCD), a severe complication of Crohn's Disease with no approved pharmacologic therapies [S1].
• Ontunisertib is designed to act locally in the gastrointestinal tract with rapid liver inactivation to avoid systemic toxicities associated with TGFβ inhibition [S1].
• The STENOVA Phase 2a trial of ontunisertib enrolled 103 FSCD patients and achieved its primary endpoint of safety and tolerability, with balanced adverse events across treatment arms and placebo [S1].
• Pharmacokinetic data from STENOVA confirmed the gastrointestinal-restricted profile of ontunisertib with high local and low systemic exposure [S1].
• Positive signals were observed on exploratory clinical endpoints in the STENOVA trial; the 48-week open-label extension results are expected in the second half of 2026 [S1].
• Agomab is preparing to initiate a Phase 2b trial of ontunisertib in symptomatic FSCD patients in the second half of 2026 based on STENOVA results and FDA interactions [S1].
• AGMB-447 is an inhaled small molecule inhibitor of ALK5 in development for idiopathic pulmonary fibrosis (IPF), a rare progressive fibrotic lung disease with poor prognosis and limited treatment options [S1].
• AGMB-447 is designed for high lung exposure with rapid hydrolysis and inactivation in systemic circulation to minimize systemic toxicity [S1].
• Preclinical studies demonstrated antifibrotic activity of AGMB-447 in rodent IPF models and human lung tissue, with no observed cardiac valve toxicities in toxicology studies [S1].
• AGMB-447 received Orphan Drug Designation from the FDA for IPF treatment in May 2024 [S1].
• A Phase 1 randomized, double-blind, placebo-controlled trial of AGMB-447 is ongoing, with positive interim results in healthy participants; data from IPF patients are expected in the second half of 2026 [S1].
• Agomab has a discovery pipeline including AGMB-101, an HGF-mimetic monoclonal antibody in preclinical development for liver cirrhosis, with regulatory clearance to proceed with a Phase 1 trial [S1].
• The company relies on third-party contract development and manufacturing organizations (CDMOs) for manufacturing APIs and inhalation devices, with no current plans to establish own manufacturing facilities [S1].
• Agomab holds intellectual property rights including a U.S. patent for AGMB-447, its inhaled lung-restricted ALK5 inhibitor [N2].
• The company faces competition from large pharmaceutical companies and smaller biotech firms developing therapies targeting fibrosis and inflammatory bowel disease, including companies developing ALK5 inhibitors and gastrointestinal-restricted therapies [S1].
• Agomab's financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice [financial_disclosure].
• No financial figures such as revenue, net income, or liquidity ratios were disclosed in the latest SEC filings [sec_financial_snapshot].